GlassScriptPhysician profile
Dana Feigenbaum
NPI 1740675347
$5,060.03
in general payments reported to CMS, 2019-2025
24 companies · $1,261 in 2025
The $1,261 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $130 · 2021: $163 · 2022: $705 · 2023: $1,318 · 2024: $1,320 · 2025: $1,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,883 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,882.94 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $977.00 | 2019-2025 | |
| Leo Pharma INC. | $608.89 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $498.82 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $319.91 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $314.86 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $275.56 | 2024-2025 | Zoryve |
| Pfizer INC. | $254.85 | 2022-2025 | |
| Amgen INC. | $221.12 | 2022-2025 | Otezla, Otezla |
| Merz North America, INC. | $220.21 | 2020-2023 | Xeomin |
| Sun Pharmaceutical Industries INC. | $217.51 | 2022-2025 | Odomzo, Blu-U, Ilumya |
| Genzyme Corporation | $213.32 | 2022-2025 | |
| Galderma Laboratories, L.P. | $161.18 | 2024-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $143.43 | 2022-2025 | |
| Janssen Biotech, INC. | $110.57 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $110.49 | 2022-2025 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $72.80 | 2025 | Vtama |
| Allergan, INC. | $71.96 | 2019-2022 | |
| Biofrontera INC. | $69.67 | 2024-2025 | Rhodoled Xl, Ameluz, Xepi |
| E.R. Squibb & Sons, L.L.C. | $53.04 | 2022 | |
| Ucb, INC. | $32.91 | 2024 | Bimzelx |
| Genentech USA, INC. | $30.51 | 2023 | Xolair |
| Strata Skin Sciences, INC. | $29.48 | 2023 | Xtrac |
| Krystal Biotech INC | $27.83 | 2024 | Vyjuvek |
| Almirall LLC | $24.11 | 2023 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Feigenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.